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Graphical Abstract 
 
Abstract 
Macrophages, named for their phagocytic ability, participate in homeostasis, tissue 
regeneration and inflammatory responses. Bone and adjacent marrow contain multiple 
functionally unique resident tissue macrophage subsets which maintain and regulate 
anatomically distinct niche environments within these interconnected Tissues. Three bone-
bone marrow resident tissue macrophages have been characterised; erythroblastic island 
macrophages, haematopoietic stem cell niche macrophages and osteal macrophages. The role 
of these macrophages in controlling homeostasis and repair in bone and bone marrow niches 
is reviewed in detail. 
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1. Introduction 
1.1 Interdependence of Bone and Bone Marrow 
Bone marrow (BM), the principal haematopoietic organ in adults, is encased within bone, the 
primary function of which is to provide mechanical support and contribute to endocrine 
homeostasis. The bone is not just an inert site of residence for BM; they are interdependent 
organs that have reciprocal regulatory mechanisms throughout life [1].  Parallel functional 
decline in both systems is a major contributor to loss of productivity and well-being during 
aging [2] and disease [3, 4]. Clear understanding of the cellular and molecular mechanisms 
responsible for the reciprocity is lacking. Herein we will discuss accumulating evidence 
suggesting that macrophages are a cellular link between these organs, focusing on 
macrophage contributions to haematopoietic systems within the BM as well as homeostasis 
and repair of bone. 
 
1.2 Resident Tissue Macrophages 
Macrophages, first described by Élie Metchnikoff, form a heterogeneous population of cells 
with diverse and adaptive transcriptomes [5, 6]. All tissues of the body contain resident tissue 
macrophages, with hyaline cartilage being the possible exception. Resident tissue 
macrophages play significant roles in tissue/niche homeostasis, phagocytosis of cellular 
debris, tissue damage/injury repair, immune surveillance and inflammation resolution [7, 8]. 
The mononuclear phagocyte system (MPS) was proposed to encompass this collection of 
functionally disparate but related cells. The MPS conceptualized that in postnatal tissues 
macrophages are continually replenished from blood monocytes derived from BM 
haematopoiesis [9, 10]. Recent ontogeny studies have indicated that self-renewal of tissue 
macrophages also contributes to homeostasis [11-13]. Only one of these ontogeny studies has 
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attempted to map BM macrophage origin [11] and showed that a subset of BM macrophages 
can self-repopulate while ontogeny of bone resident macrophages (osteal macrophages, 
osteomacs) has not been investigated. 
 
1.3 Macrophages within the Bone and Marrow Environment 
BM topography is subtle and complex, involving an intricate patchwork of functionally 
designated microenvironments/niches [14]. The BM and bone contain multiple distinct 
resident macrophage populations that contribute to these specific niches and their specialised 
functions. The first recognised resident macrophages within BM stroma were the central 
macrophages within erythroblastic islands (erythroblastic island macrophages, EIM) [15]. A 
more recent discovery is the BM resident macrophage population involved in maintenance of 
hematopoietic stem cell (HSC) [16] that will be referred to here as HSC niche macrophages. 
Lastly, osteomacs, reside within the specialised tissues lining bone, including the endosteum 
which is continuous with adjacent BM [17]. See Figure 1 for schematic representation of the 
confirmed macrophage subsets within bone and BM. Given the large number of functional 
niches within BM and bone, it is likely that new resident macrophage subsets will emerge. 
 
1.4 In Vivo Models of Macrophage Depletion 
In vivo mouse models of macrophage depletion have been used to study functional 
contributions of macrophages to erythropoiesis, HSC niches as well as bone homeostasis and 
repair. The Mafia (macrophage Fas induced apoptosis) transgenic mice contain a drug-
inducible Fas suicide gene regulated by the c-fms promoter [16, 18, 19]. Inducible and 
efficient broad spectrum macrophage depletion is achieved in many tissues (significant 
reductions in F4/80+ cells) [20] including BM macrophages [16, 20, 21] and osteomacs [18, 
21]. However depletion efficacy within specific BM macrophage subsets has not been 
 6 
 
explicitly reported and warrants more rigorous attention given recent improvements in subset 
phenotyping, as detailed below. Caution is needed when using the Mafia model as the 
transgene is also expressed by CD11b+ myeloid cells including monocytes and myeloid 
precursors [16, 20], osteoclasts [19], granulocytes [16, 20]and dendritic cells [16, 20, 22]. 
Macrophage recovery occurs rapidly if depleting agent delivery is ceased [19, 20].  
 
Clodronate liposomes have been used extensively to deplete macrophages in vivo [23] 
including those in bone [18, 19, 21] and BM [16, 24, 25]. Internalisation of the clodronate-
loaded liposome is required for apoptosis induction and consequently professional 
phagocytes are preferentially depleted in this model [23]. Consequently phagocytic potential 
of different macrophage subsets dictates depletion kinetics and sensitivity. For example, in 
BM EIM are particularly susceptible to clodronate liposomes [16], but granulocytes [16] and 
myeloid precursors are preserved. Both osteomacs and osteoclasts are efficiently depleted by 
clodronate liposomes [26]. An additional nuance of this model is that delivery route and 
delivery dose/regimen impact on the macrophage depletion specificity and sensitivity 
including target organ variation [21, 23]. As discussed in detail below, both the Mafia model 
and clodronate liposome delivery induce HSC mobilisation, implying that both approaches 
target HSC niche macrophages. 
 
The CD169-diphtheria toxin (DT) receptor (DTR) mouse is a more refined in vivo 
macrophage depletion tool [27]. It is a knock in model where human DTR cDNA has been 
recombined into the mouse CD169 gene. Thus DTR expression is regulated by the 
endogenous CD169 promoter. CD169 expression is restricted to a subset of tissue 
macrophages and is expressed by approximately 30% of BM F4/80+ cells which includes 
HSC niche macrophages [28], EIM [24] and osteomacs [26]. This model avoids many 
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undesired off-macrophage targets, including osteoclasts [26]. Other models of in vivo 
macrophage depletion have also been employed, but have yet to be rigorously characterised 
or broadly reproduced [29]. 
 
2. Macrophages and Erythropoiesis 
2.1 Role of EIM in Regulating Erythroblastic Island Niches 
Erythroblastic islands comprise a central macrophage clustering numerous erythroblasts 
spanning the multistep erythroid maturation process (Figure 1) [15]. EIM are essential for 
erythroblasts survival during their maturation to generate functional enucleated reticulocytes. 
The function of EIM, recently reviewed in detail [30], falls into three broad categories: a) 
secretion of trophic cytokines, b) iron transport [31], and c) phagocytosis and degradation of 
extruded nuclei [32, 33]. BM macrophages can express erythropoietin (EPO) [34, 35] the 
principal growth factor regulating erythropoiesis. Macrophages are also EPO responsive 
suggesting complex feedback loops may exist in response to EPO regulation of erythroid 
islands [36]. Macrophages can also express other factors that promote erythropoiesis 
including insulin-like growth factor-1[37, 38] and bone morphogenetic protein (BMP) 4 [39], 
but direct confirmation of EIM expression and necessity for erythroid island integrity is 
lacking. Interestingly, all of the molecules have also been implicated in bone biology with 
dominant pro-anabolic effects [40-42] with the latter two also implicated in HSC homeostasis 
[43-45]. EIM also contribute to heme synthesis and iron recycling by incorporating iron into 
ferritin. The ferritin is then transported to erythroblasts for the synthesis of large amounts of 
hemoglobin [46]. Finally, through complex adhesion interactions the EIM aid in the 
enucleation process and ultimately phagocytosis and degradation of the approximate 200 
billion daily extruded pyrenocytes [32, 33]. Failure in this function derails erythropoiesis and 
leads to severe anaemia [33, 47].  
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The importance of these EIM niche roles was recently validated through robust and sustained 
in vivo depletion of EIM results in collapse of BM erythropoiesis with loss of all maturation 
stages of erythroblasts and reticulocytes while pro-erythroblasts were unaffected [24, 48]. 
The loss of erythrocyte production within BM did not produce peripheral anaemia, 
presumably through a combination of extramedullary erythropoiesis and increased 
erythrocyte lifespan [48]. Repeat transient macrophage depletion via intermittent treatment 
with clodronate liposome (engulfment causes apoptosis of macrophages) did not reduce the 
number of BM erythrocytes but did result in decreased hemoglobin concentration and mean 
hemoglobin content, supporting the important role of EIM in erythrocyte hemoglobin 
synthesis [49].   
 
Phenotypic profiling of EIM has recently advanced to reveal a unique combination of typical 
myeloid-macrophage markers including CD11b, F4/80 (Figure 2A, circle) and CD169 [24, 
48] plus the EIM-associated antigen ER-HR3 (Figure 2B, circle) [50] in combination with the 
traditional granulocyte antigen Ly6G [24]. They also express adhesion molecules such as 
vascular cell adhesion molecule (VCAM)-1 [24, 51] which mediates erythroblast adhesion to 
EIM [51, 52]. The improved knowledge of EIM identity will inform more elegant approaches 
to elucidating EIM biology and disrupted mechanisms in blood diseases. 
 
2.2 Role of EIM in Stress-Induced Erythropoiesis and Blood Diseases  
Erythropoiesis is increased in response to circumstances that place elevated pressure and/or 
attrition on erythrocyte supply, including blood loss, anaemia, disease/infection, or after 
exposure to exogenous factors (e.g. recombinant EPO). These stressors often drive 
extramedullary blood production to rapidly expand erythropoietic capacity [49]. Recent 
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studies have confirmed the critical role of EIM in stress-induced erythropoiesis. Macrophage 
depletion either prior to or after phlebotomy-induced anaemia [48, 49], phenylhydrazine-
induce haemolytic anaemia [48] or exogenous EPO driven erythropoiesis [49] significantly 
impaired erythropoietic recovery. 
 
Relative expression levels of specific transcription factors (e.g. Gata1 and PU.1) regulate the 
counterbalance between erythropoiesis and myelopoiesis [45, 53], presumably to protect the 
HSC pool from exhaustion (discussed in section 3.1). As EIM express pattern recognition 
receptors and granulocyte-colony stimulating factor (G-CSF) receptors, they are well placed 
to adapt erythropoiesis to inflammation and infections that generally cause a high demand on 
myelopoiesis. For instance, G-CSF is abundantly released in the circulation following acute 
inflammation and infections and drives granulocyte production, maturation and survival. G-
CSF also causes a profound loss of EIM in the BM resulting in a complete shut-down of 
medullar erythropoiesis [24]. Bacterial lipopolysaccharides (LPS) cause a similar loss of 
medullar EIM and erythropoiesis, an effect mediated by toll like receptor 4 (TLR4) [54]. 
 
The essential role of EIM in regulating and supporting erythropoiesis makes them a viable 
therapeutic target in diseases of either hyper- or hypo-erythrocyte production/deficiency. 
Liposome encapsulated EPO was targeted to erythroid islands via EIM phagocytosis and was 
more effective than systemic recombinant EPO delivery in a model of renal anaemia [55]. 
Conversely, depletion of EIM in mouse models of polycythaemia vera [48, 49] and β-
thalassemia [49] reduced the elevated erythropoietic activity associated with these 
pathological conditions [49]. Therapeutic feasibility and efficacy of targeting EIM in blood 
diseases warrants further investigation. 
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3. Macrophages and Haematopoiesis 
3.1 HSC Niche Regulation by Resident BM Macrophages During Homeostasis 
HSC reside within the mammalian BM and by definition have both life-long self-renewal 
potential and the capacity to produce all cells required to replenish the blood and immune 
systems throughout life. Thus HSC must balance conflicting demands of self-renewal and 
extensive proliferation to replenish exhausted leukocytes and erythrocytes. Prolonged 
extensive HSC proliferation can produce progressive exhaustion of the HSC pool leading to 
BM failure. To meet these conflicting demands, a pool of HSC remains dormant/quiescent, 
acting as a back-up against progressive exhaustion [56, 57]. This store of dormant HSC can 
be rapidly recruited to proliferate in response to stress if required, and return to dormancy 
once the challenge is resolved [56]. Both intrinsic and extrinsic factors determine HSC fate 
decisions and it is likely that different types of niches make substantial contributions toward 
imposing and supporting these different fates [58, 59]. 
 
Separate niches have been defined within the BM that harbor either active HSC or dormant 
HSC (Figure 1). The precise location, support cell constitution and extrinsic molecular 
mediators controlling HSC within these two niches remain controversial [60, 61]. Enrichment 
of HSC has been reported within the metaphyseal endosteal arteriolar regions [60-64] or 
within peri-sinusoidal niches [60, 61, 65, 66]. The endosteal hypoxic areas of BM may be 
associated with low blood perfusion and dormant HSC [56, 58, 63, 67, 68]. Whole mount 
imaging of bone and BM provided additional evidence that quiescent HSC are enriched in the 
endosteal region adjacent to arterioles [62], while cycling/active HSC located near peri-
sinusoidal niches where their greater metabolic demand is better served by higher oxygen 
content [59, 60, 62]. Within this hierarchy of niches (Figure 1), HSC are supported by 
specific stromal cells including mesenchymal stem/progenitor cells and pericytes (nestin+ or 
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leptin receptor+), early committed osteolineage progenitors (osterix+ cells), non-myelinating 
Schwann cells, sympathetic nerves and endothelial cells [69]. Macrophages also contribute to 
HSC niche homeostasis [16, 28, 70, 71] and dissection of their specific niche functional 
contributions and molecular mediators is in its infancy [60]. All these elements coalesce to 
create a complex regulatory network influencing HSC quiescence, proliferation, and self-
renewal [60, 61]. 
 
Macrophages are localised in HSC niche microenvironments (Figure 2) [18] and support 
other niche cellular components in vitro [16, 18, 72]. Their likely function has been assessed 
using in vivo models of macrophage depletion, including Mafia transgenic mice (contains 
drug-inducible Fas suicide gene regulated by c-fms promoter) [16], clodronate liposome in 
wild type mice [16, 28], or CD11b- and CD169-based inducible depletion mouse models 
[28]. Macrophage depletion disrupted endosteal HSC niche components including 
suppression of osteoblast lineage cells and down regulation of HSC retaining factors [16, 18]. 
This subsequently induced HSC niche collapse leading to HSC mobilisation from BM to 
blood and extramedullary lymphoid organs [16, 28]. Additionally, as discussed in Section 3.2 
below, these observations were further validated in models of haematopoietic stress [16, 70]. 
 
 The unique HSC niche macrophages phenotype is still uncertain. Winkler et. al. first 
demonstrated that collapse of HSC niches was instigated by depletion of a mixed population 
of CD11b+F4/80+ cells that had variable Ly6G expression [16]. While they also express 
CD115, major histocompatibility complex class II and CD68, expression of CD169 provided 
clear distinction of HSC niche macrophages from other BM myeloid populations including 
monocytes [28] but not necessarily from other BM resident macrophages. Subsequent studies 
achieved further honing of HSC niche macrophage phenotype by a process of elimination as 
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CD169+Ly6G+ BM macrophages were confirmed to be EIM. Dutta et. al. demonstrated the 
macrophage expression of VCAM-1 was important for retention of HSC in splenic 
myelopoiesis niches [73], which likely extrapolates to BM niches but expression overlaps 
with EIM [24]. Finally, Hur et. al. showed that CD234 (also known as duffy antigen receptor 
for chemokines, DARC) is expressed by macrophages that are in direct contact with 
quiescent HSC [74], although caution is needed as its expression is not myeloid restricted 
[75]. In summary, HSC niche macrophages of the mouse are currently defined as 
CD11b+F4/80+Ly6GnegCD169+VCAM-1+CD234+ BM macrophages. It is yet to be 
determined whether this subpopulation encompasses a phenotypically and/or functionally 
homogenous subset and functional confirmation of this subset as the only BM macrophage 
subset required for HSC niche maintenance is lacking. Given HSC mobilisation efficiency 
reduced concomitantly with the narrowing of the specificity of macrophage in vivo depletion 
in models [28], there is likely to be at least some redundancy, if not diversity, in HSC niche 
macrophages, creating resilience in the HSC niche system. 
 
Evidence suggests that HSC niche macrophages regulate HSC via both direct [74] and 
indirect (i.e via other niche support cells) [16, 28, 72] actions. Hur et. al. have demonstrated 
that binding of CD234 on HSC niche macrophages stabilises surface CD82 expressed by long 
term (LT)-HSC residing in endosteal arteriolar regions of the BM [74] and promotes HSC 
quiescence. Depletion of CD169+ macrophages, which included depletion of CD234+ BM 
macrophages, decreased HSC cell surface CD82 and increased their proliferation and 
differentiation [74]. Independent validation of these observations is needed, especially given 
other niche components have also been reported to express CD234 [75]. 
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HSC niche macrophage support of osteoblast lineage cells has also be implicated in HSC 
niche regulation [16] and the specific cellular and molecular mechanisms will be discussed in 
more detail in Section 4. Of specific relevance here, loss of p62 (also known as 
sequestosome-1; major role in ubiquitinated protein turnover through autophagy pathways) in 
osteoblasts upregulated nuclear factor (NF)-κB signalling which subsequently inhibited 
osteoblast differentiation and C-C motif chemokine (CCL-4) production [72]. This in turn 
modulated BM hematopoietic stem and progenitor cell (HSPC) chemotactic response to 
CXCL12 [76] and resulted in increased traffic of HSPC out of the BM [72]. Importantly, 
direct cell contact with macrophages sustained the required low level NF-κB activity in 
osteoblasts, via p62, needed to support osteoblast maintenance and homeostasis [72]. 
Similarly, Chow et al, indicated that HSC niche supportive BM macrophages provided 
indirect support through Nestin+ mesenchymal stem cells with macrophage depletion 
significantly reducing expression of HSC retention molecule genes such as Cxcl12, Angpt1, 
Kitl and Vcam1 in Nestin+ mesenchymal stem cells coupled with reduced HSC-attracting C-
X-C motif chemokine ligand (CXCL)12 expression in BM stromal cells [28]. HSC niche 
macrophages appear to be the primary sensors of homeostatic mechanisms that influence the 
size and activity of the HSC niche pool. Specifically, circadian rhythms that influence HSPC 
egress into the circulation are triggered by macrophage elimination of aged neutrophils in the 
BM [77]. This mechanism could also provide feedback to BM HSC niches to meet increased 
haematopoietic demand created by distant tissue injury or infection [77].  
 
3.2 HSC Niche Maintenance by Macrophages during BM Stress 
Evidence supports that HSC niche macrophages respond directly to stimuli in times of BM 
injury, infection or inflammation and translate these stress signals to modulate HSC niche 
dynamics to achieve ‘emergency hematopoiesis’. An equally important outcome is whether 
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HSC niche macrophages orchestrate protection of the pool of long-term repopulating HSC 
(LT-HSC) required for longevity of the haematopoietic system. Exposure to the pro-
inflammatory factor G-CSF, which is commonly used to mobilized HSC for collection and 
subsequent clinical transplantation [78], substantially reduced BM [16] but not splenic [24] 
macrophages. This suggests that G-CSF may selectively target BM HSC niche macrophages 
resulting in a site-specific adaptation to this stressor. The loss of BM macrophages triggered 
loss of osteoblast lineage cells and concomitantly reduced HSC niche regulating factors in the 
BM [16] and induced HSC to proliferate [79]. This response was dependent on G-CSF 
receptor expression by CD68+ macrophages [70]. Human monocytes and macrophages also 
express high levels of G-CSF receptor mRNA [80] indicating this response is unlikely to be 
species specific.   
 
Chemotherapy treatment, using either cyclophosphamide [71] or 5-fluorouracil [74], appears 
to trigger a similar cascade of HSC niche collapse. In both cases BM macrophages and HSC 
transiently resist the myeloablative treatment but once BM macrophages succumb, HSC 
egress from BM rapidly follows [71, 74]. These observations suggest that there is a threshold 
of BM stress, and once reached the BM is no longer a viable environment for HSC residence 
and that macrophages may be a key element of the rheostat monitoring this stress threshold. 
Once the threshold is reached, HSC mobilisation occurs so that other suitable non-BM niches 
can be temporarily engrafted and extramedullary haematopoiesis initiated to sustain blood 
and immune cell supply. Given evolutionary pressure to sustain haematopoiesis, it is likely 
that multiple different mechanisms exist to protect HSC integrity. In a murine bacterial 
infection model, interferon-γ increased the number of BM macrophages but this was 
associated with a decrease in the BM HSC pool [25, 81]. It was postulated that the expanded 
macrophage subset, which was driven by interferon-γ, promoted HSC quiescence/dormancy 
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[25], similar to recent functional characterisation of CD234+ BM HSC niche macrophages 
[75]. This may be a mechanisms to protect the LT-HSC pool in the context of systemic 
infection that has compromised both BM and/or other suitable extramedullary niches [81].  
 
Following a period of increased demand for haematopoiesis, the HSC niche must recover. 
This process is clinically relevant in BM transplantation and during recovery from 
chemotherapy. F4/80+ macrophages were one of the first cells to repopulate the endosteal 
environment following cessation of a mobilising G-CSF regimen [16], followed by expansion 
of osteoblast-lineage cells and recovered HSC niche factor expression [16, 71]. HSC niche 
reassembly is presumably a pre-requisite for recreating a permissive environment for HSC to 
repopulate BM post mobilization, a phenomenon that may extend to HSC transplantation 
settings. This possibility somewhat mimics the primordial wave where resident tissue 
macrophages exist in developing embryos prior to definitive haematopoiesis [12, 82]. Indeed, 
the fact that F4/80+ macrophages are the first mature cell output of haematopoiesis and form 
the centre of embryonic haematopoietic islands in the foetal liver [83] is also suggestive of 
macrophages being a focal point for HSC niche formation. Embryonic macrophages also 
degrade extracellular matrix with matrix metalloproteinase (MMP)-9, aiding HSC migration 
from the aorta-gonad-mesonephros to haematopoietic organs [84] where they establish 
definitive haematopoiesis. Even though the post-transplant BM environment is vastly 
different to the developing embryo, BM macrophages have been reported to survive lethal 
doses of irradiation [11, 85] and potentially chemotherapeutic drugs [71, 74] suggesting they 
are at least available to contribute to reformation of HSC niches after these stressors. In fact, 
radiation induced injury or 16,16-dimethyl prostaglandin (PG) E2 treatment upregulated 
cyclooxygenase-2 (COX-2) expression in α-SMA+ BM macrophages which further enhanced 
PGE2 production [86] and improved the homing, survival and proliferation of PGE2 receptor 
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expressing HSC post-transplant [87]. This pathway is unlikely to be restricted to α-SMA+ 
macrophages as many other macrophage populations express COX-2 in response to 
inflammation or tissue injury [88, 89]. Clear understanding of resilience or recovery of HSC 
niche macrophages post-transplantation may reveal therapeutic strategies for improving 
transplantation outcomes or reducing the toxicity of chemotherapy. 
 
4. Macrophages in Bone Homeostasis and Bone Repair 
4.1 Osteal Macrophages  
Bone is a dynamic tissue that undergoes continual adaptation during vertebrate life to 
maintain structural integrity, regenerate in response to damage and regulate mineral 
homeostasis. Homeostatic control of bone integrity involves the balanced interaction of 
matrix forming (mesenchymal) and matrix degrading (haematopoietic) cells. Osteoblast 
lineage cells develop through a multi-stage maturation progressing from relatively inactive 
bone-lining cells to bone forming osteoblasts and subsequently, a portion of these, undergo 
terminal differentiation into osteocytes. The latter form a cellular network within the 
mineralized matrix from where they detect mechanical strain and damage. Both osteoblasts 
and osteocytes contribute to incorporation of mineral into the bone organic matrix [90, 91]. 
Chondrocytes are responsible for production of cartilage matrix which is used as an 
intermediary structure during bone formation via endochondral ossification. Osteoclasts are 
terminally differentiated multinucleated myeloid lineage cells responsible for removal of 
bone matrix. In the early 1980s, a candidate third participant in bone homeostasis was 
identified in the form of a periosteal F4/80+ macrophage population [92]. The distribution and 
function of these cells, termed osteomacs, in bone homeostasis and repair has become clear 
from more recent studies [17, 93, 94].  
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Dynamic events in bone often occur in a coordinated site-specific manner with bone surfaces 
referred to as either resting or active (Figure 1). On resting bone surfaces, the bone lining 
tissues consists of osterix+ bone lining cells interspersed by osteomacs. The endosteum (bone 
surface in contact with the BM) at resting sites is a single cell layer and therefore osteomacs 
are in direct contact with the bone surface (Figure 1 and [18]). The periosteum (peripheral 
bone surface in contact with skeletal muscle) is more complex including an inner cambium 
and outer capsule layers (Figure 2D). The cambium contains osteomacs (Figure 2D, arrows) 
while the capsule contains a potentially distinct F4/80+ resident tissue macrophage population 
(Figure 2D, arrowheads). Osteomacs express a suite of common pan-macrophage markers 
including F4/80, CD115, CD68 and Mac-3 but do not express the osteoclast marker tartrate-
resistant acid phosphatase [17, 18, 24, 94] or osteoblast lineage markers [18]. An equivalent 
CD68+ osteomac population was also detected in human endosteum in normal bone [18] and 
pathological bone formation associated with prostate cancer [26]. Thus far, no unique marker 
distinguishes osteomacs from other BM macrophage subsets, but unlike EIM, endosteal 
osteomacs do not express the ER-HR3 antigen (Figure 2A and B, arrows). Therefore 
definitive designation of osteomacs currently requires confirmation of their anatomical 
location (within 3 cell diameters of a bone surface). This limitation continues to hinder 
characterization of the osteomac-specific molecular signature and consequently the molecules 
involved in mediating their bone specific functions. 
 
4.2 The Role of Osteomacs in Bone Formation 
Despite limited molecular characterisation of osteomacs, their striking distribution at sites of 
bone formation provided insight into at least one of their functional roles in bone [18]. At 
active bone forming sites on endosteal (Figure 2A and C) and periosteal (Figure 2D-F) 
surfaces osteomacs are intimately associated with bone forming osteoblasts, including 
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formation of a canopy-like structure over endosteal modelling surfaces (Figure 2A and C, 
arrows). Given the endosteum is continuous with adjacent BM and that many molecular 
mediators have activity in both bone and BM homeostasis, it is possible that the site specific 
formation of a continuous layer of endosteal osteomacs achieves microenvironmental 
partitioning by forming a phagocytic barrier (Figure 1). This barrier may be needed to 
prevent inappropriate disturbances within the adjacent BM as a bystander impact of bone 
dynamics.   
 
In vitro evidence using both human and mouse  macrophages [18, 29, 72, 95-99], including 
primary macrophages isolated from bone tissues [18], demonstrated that these cells promote 
mesenchymal maturation along the osteoblast lineage and/or osteoblast functional maturation. 
Osteomacs are also integral for parathyroid hormone anabolic actions [21]. It is unclear 
whether direct cell contact is necessary [72] or if secreted factors [18, 29, 72, 95-99] or even 
monocyte/macrophage exosomes [100] can at least partially mediate these macrophage 
actions. However, it is clear that macrophages can provide pro-anabolic support to osteoblasts 
and that osteomacs are appropriately located to achieve this function in vivo. Only two 
macrophage-derived molecules have been directly implicated in driving osteoblast 
maturation: oncostatin M [96] and bone morphogenetic protein-2 [98]. It is unlikely that a 
single molecular pathway is responsible for pro-anabolic effects of macrophages on 
osteoblasts, as macrophages under various conditions can express a wide array of pro-
anabolic molecules.  
 
The extrinsic stimuli that promote pro-bone anabolic function in macrophages are not well 
defined. We originally showed that elevated extracellular calcium, as would be expected at 
sites of bone remodelling [93], greatly enhanced macrophage pro-anabolic function [18]. The 
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pro-inflammatory stimulus LPS also promoted human monocyte/macrophage support of 
osteoblast differentiation and function [96]. This outcome was somewhat unexpected given 
that chronic inflammation generally causes bone loss and LPS delivery is used as an in vivo 
bone loss model [101]. Recently, Michalski et. al. observed that CD206+ anti-
inflammatory/reparative macrophages secrete the pro-anabolic molecule transforming growth 
factor (TGF)-β1 after efferocytosis of apoptotic osteoblasts  [102]. This potential feedback 
loop could extend bone formation beyond the functional lifespan of the first wave of 
osteoblasts at any given anabolic site, consistent with the more extended time required to 
complete bone formation in comparison to bone resorption [93]. Macrophages play a vital 
role in monitoring the microbiota, and this has been shown to impact on homeostatic 
mechanisms within the gut [103].  Macrophages could also contribute to impacts of 
microbiota on bone [104] but direct evidence is lacking. More refined in vivo studies research 
are needed to better characterise extrinsic signal impacts on osteomac/macrophage functional 
polarization and how this influences bone homeostasis. 
 
In vivo approaches using inducible or targeted macrophage depletion strategies in mouse 
models have provided confirmation of osteomac/macrophage pro-anabolic function. This was 
first shown using the Mafia mouse model in which induced conditional depletion of 
macrophages resulted in rapid loss of osteoblast bone-forming surface [16, 18, 21] and 
blunted the anabolic actions of parathyroid hormone [21]. An alternative approach used a 
transgenic mouse in which lysozyme M drives expression of diphtheria toxin causing cell 
death. Bone-BM macrophages were at best reduced by approximately 50% but a significant 
bone growth and formation phenotype was observed [29]. Studies using clodronate liposomes 
have produced mixed outcomes [16, 21]. Short-term, aggressive treatment with clodronate 
liposomes recapitulated the Mafia model [16]. However, a long-term reduced treatment 
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schedule was unexpectedly bone anabolic due to a compensatory expansion of CD68+ 
phagocytic macrophages that was accompanied by an increase in the osteogenic factors Wnt-
3a, Wnt-10b and TGF-β1 within the bone-BM environment [21]. As discussed in section 3.2, 
HSC mobilising regimens of G-CSF resulted in robust depletion of bone-BM macrophages. 
This was associated with loss of osteoblast bone surface and a reduced bone formation rate 
[58, 71]. Interestingly, G-CSF treatment does not deplete macrophages in spleen [24] and has 
limited impact on osteoclasts [16], suggesting its actions on macrophages may be restricted to 
bone-BM. G-CSF was reported to induce changes in osteocyte biology [105] which may 
provide some explanation as to why its effects are more site restricted that other in vivo 
macrophage targeted models. The same study demonstrated that targeted depletion of 
osteocytes resulted in loss of osteomacs [105] implicating cross talk between not only 
macrophages and osteoblasts on the bone surface, but direct communication between 
osteocytes and osteomacs.  
 
Expansion of macrophages also provides tentative evidence supporting macrophage pro-
anabolic function. Macrophage proliferation and differentiation is controlled by CSF-1 [106]. 
CSF-1 is also required to generate progenitors for osteoclasts, and CSF-1-deficient mice are 
severely osteoclast deficient [107]. However, CSF-1 alone cannot increase osteoclast 
formation in vivo, even in a pro-inflammatory environment [108]. Exogenous CSF-1 
increases systemic and/or local bone volume in a number of models [109-112]. The anabolic 
actions of CSF-1 have been assumed to be due to increased osteoclast-osteoblast coupling 
and consequently enhanced remodelling, without consideration of the potential role of 
osteomacs or other macrophage subsets.  
 
4.3 Role of Osteomacs and Inflammatory Macrophages in Bone Repair 
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Macrophages are central contributors to reparative inflammation, coordinating both the injury 
response and tissue regeneration [113]. Bone fracture causes disruption of local tissue 
vasculature, soft and hard tissue integrity, BM architecture and induces hematoma formation. 
Resident macrophages initiate a cascade of growth factor, inflammatory cytokine and 
chemokine production that facilitate recruitment of inflammatory immune cells that combat 
infection and phagocytose debris and dead cell remnants [114]. The inflammatory event 
drives expansion/recruitment of endothelial, neuronal and mesenchymal 
stem/progenitor/precursor cells leading to replacement of the hematoma with a vascularized 
and innervated fibrous granulation tissue [114]. Anabolic healing mechanisms are initiated at 
the fracture site and are influenced by fracture biomechanics, with high rigidity fractures 
favouring direct bridging by intramembranous ossification and low rigidity fractures healing 
via periosteal callus formation through endochondral ossification. A structurally viable callus 
is formed which is gradually remodelled to reinstate normal bone architecture. Thus fractures 
heal via sequential progression through phases of inflammation, early anabolic, late anabolic 
and remodelling.  
 
Macrophages, including both osteomacs and inflammatory macrophages, are present during 
all phases of fracture repair and associate with key repair events in animal models [19, 109] 
and human tissues [115]. Inflammatory macrophages are anatomically positioned to support 
key events in the inflammation and early anabolic phases [19]. Osteomacs predominate in the 
late anabolic [19, 109] and remodelling phases [19, 109] and are specifically associated with 
maturing bone within the callus [19]. In bone repair/fracture models various broad spectrum 
myeloid depletion approaches indicate macrophage requirement for initiation and osteomac 
requirement for optimal progression of fracture healing [19, 29, 109, 116] with repair 
outcomes proportionate to the number of local participating osteomacs/macrophages [19]. 
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Local administration of CSF-1 in both a tibial injury [109] and a femoral fracture model [19] 
increased the number of fracture-associated F4/80+ macrophages, without a concomitant 
increase in osteoclasts, and significantly increased boney bridging and soft-callus formation, 
respectively. Furthermore, systemic treatment with CSF-1 in the first 2 weeks post fracture in 
a rabbit bone injury model resulted in increased mineralized callus at 8 weeks post-fracture 
[117]. CSF-1 treatment has already been shown to be safe and efficacious in humans [118]. 
Based on this evidence CSF-1 treatment is a candidate therapy for fracture repair. Using a 
tibial injury model, Guihard et. al. recently showed, that macrophage production of the 
anabolic molecule oncostatin M and subsequent STAT3 activation promoted bone healing 
[119] and therefore more specific therapies based on macrophage pro-anabolic stimuli may 
be an alternative approach.  
 
5. Conclusions and Conundrums  
In the last 10 years significant leaps have been made in the appreciation of macrophage 
contributions to bone and BM homeostasis and health. Improved characterisation of BM and 
bone resident macrophage subsets is needed at both the functional and molecular level to 
reveal the entirety and complexity of the resident macrophage subsets in these physically 
linked organs. Distinct niches in endosteum and BM may differentially support the various 
hematopoietic stem and committed progenitor populations [68, 120]. The specific stromal 
support cell involved within a given niche may define which stem/progenitor cell is 
preferentially supported [121]. A similarly hierarchy of BM niche supportive macrophage 
subsets may also exist. Macrophage contributions to the homeostasis of both bone and BM 
clearly intersect at the level of their support of osteoblast lineage cells but this is unlikely to 
be the extent of the overlap as both vascular and nerve contributions are integral to both 
 23 
 
systems and macrophages dynamically interact with both these compartments. It is clear that 
we are only scratching the surface of the complex mechanisms regulating the various niches 
within bone and BM but macrophage involvement in these niches is a common mechanism. 
Ultimately improved understanding of osteoimmunological mechanisms underlying the peak 
function and decline of bone and BM will inform approaches to achieve 
preservation/reinstatement of peak function in disease and aging.  
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Figure Legends 
 
Figure 1: Schematic representations of the confirmed resident macrophage subsets 
within bone and BM. 
Three confirmed resident macrophages subsets have been characterised within BM and bone. 
EIM are intermixed throughout the medullar clustering maturing erythroblasts and supporting 
multiple key steps in erythropoeisis. Within haematopoietic tissue within the endosteal 
microenvironment CD234+ HSC niche macrophages, and potentially even osteomacs on 
resting bone surfaces, are an integral cell participant in dormant HSC niches. These endosteal 
dormant HSC niches also require association with arterioles, innervation, early mesenchymal 
lineage cells (MC) and osterix+ osteoblast-lineage bone lining cells (BLC). Active HSC 
reside in vascular niches located adjacent to sinusoids. F4/80+ macrophages are abundant in 
this location and are presumably a CD234neg HSC niche macrophages. Again other niche 
cellular constituents including nerves and mesenchymal cells help form the specific physical 
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requirements needed to support the self-renewing and cycling HSC within these specific 
niches. Finally, osteomacs are intercalated within bone lining tissues on resting endosteal 
surfaces or reorganise to form a canopy-like structure over osteoblasts at active bone 
modelling surfaces. 
 
 
 
Figure 2: Bone and BM Resident Macrophage In Situ. 
Hind limbs were collected from 4 week old mice, fixed and processed to paraffin block and 
sections stained by a chromogen based immunohistochemistry technique as previously 
described [30]. A) F4/80 (brown) expression within endosteum and medullar environments 
exemplifying the large number of resident macrophages within these physically connected 
environments. B) EIM ER-HR3 (brown) expression in a near serial section to (A). F4/80+ER-
HR3+ EIM can be tracked (circles) whereas canopy osteomacs are clearly F4/80+ER-HR3neg 
(arrows). C) Prime example of F4/80+ (brown) osteomac canopy (arrows) at an endosteal 
modelling site partitioning the bone forming surface from the adjacent BM. D) Resting 
periosteal bone surface exemplifying its more complex structure including both F4/80+ 
osteomacs within the cambium layer (arrows) and F4/80+ capsule resident macrophages 
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(arrowheads). E) Periosteum within the dynamic corticalization zone that mediates bone 
lengthening during growth contains highly reticulated F4/80+ osteomacs within the cambium 
layer (arrows) and F4/80+ capsule resident macrophages (arrowheads). F) Near serial section 
to (E) stained with isotype matched control antibody to demonstrate specificity of staining. 
All sections were counterstained with hematoxylin (blue) and original magnification was 40x 
with digital zooming applied in (C-F). 
